ArticleScientific reports2025
Computed tomography based radiomics signature for predicting the expression of vascular endothelial growth factor in pediatric patients with nephroblastoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To construct a computed tomography (CT) based radiomics signature and assess its performance in predicting vascular endothelial growth factor (VEGF) expression in pediatric patients with nephroblastoma. A total of 73 pediatric nephroblastomaL patients were enrolled (51 in the training cohort and 22 in the test cohort). The region of interest manually marked on the CT images served as the basis for the automatic extraction of radiomics features. A radiomics score was generated utilizing the radiomics signature based formula after retaining a subset of radiomics features to create a radiomics signature. Clinical elements, such as clinicopathological information and CT imaging characteristics, were used to create a clinical model. With the inclusion of a radiomics signature and clinical characteristics, a composite nomogram was created. Decision curve analysis (DCA) was used to evaluate the prediction performance. 5 carefully chosen radiomics features were used to create the radiomics signature. Next, the radiomics score was determined. In the training cohort and the test cohort, the logistic regression model's area under the curve was 0.761 and 0.791, respectively. Based on the radiomics signature and clinical variables, the clinical radiomics nomogram demonstrated its ability to accurately predict the level of VEGF expression. DCA verified the clinical value of the clinical radiomics nomogram. In pediatric patients with nephroblastoma, the radiomics model based on the CT radiomics signature may accurately predict the level of VEGF expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.